Gilead Sciences GILD Total Liver Disease — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's total liver disease — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's total liver disease — total revenues?
- Gilead Sciences (GILD) reported total liver disease — total revenues of $767M in Q1 2026.
- How has Gilead Sciences's total liver disease — total revenues changed year-over-year?
- Gilead Sciences's total liver disease — total revenues increased by 1.2% year-over-year, from $758M to $767M.
- What is the long-term trend for Gilead Sciences's total liver disease — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's total liver disease — total revenues has grown at a 3.1% compound annual growth rate (CAGR), from $2.85B to $3.22B.
- What does total liver disease — total revenues mean?
- The total sales revenue generated from the company's portfolio of liver disease treatments.
- How do you interpret total liver disease — total revenues?
- An increase indicates growing market share, successful product adoption, or effective pricing strategies within the liver disease therapeutic area, while a decrease may signal increased competition, patent expirations, or declining patient demand.
- How does total liver disease — total revenues compare across companies?
- Comparable to revenue segments for specialized therapeutic areas in other biopharmaceutical firms, such as oncology or immunology divisions, where performance is driven by drug efficacy and market access.